Health-Related Quality of Life After the Diagnosis of Locally Advanced or Advanced Prostate Cancer: A Longitudinal Study

Approximately 20% of men with a diagnosis of prostate cancer present with locally advanced or advanced disease. Few studies consider longer-term impact of disease progression and treatment adverse effects on health-related quality of life (QoL) of these men.

Describe changes in health-related QoL over 5 years for men with newly diagnosed locally advanced or advanced prostate cancer.

Eighty-one men with locally advanced or advanced prostate cancer referred to the study by their treating urologist completed a self-administered questionnaire assessing distress, cancer-specific distress, decision regret, satisfaction with life, and global and disease-specific health-related QoL. Questionnaires were administered close to diagnosis (baseline), 2, 6, 12, 24, 36, 48, and 60 months' follow-up.

Men were of mean age 68.3 (SD, 7.9) years and at mean of 31.9 (SD, 50.5) days postdiagnosis. The most common treatment received was androgen deprivation therapy (95.1%) or radiation therapy (79%). The proportion of men classified as distressed (Distress Thermometer) ranged from 46.3% (baseline) to 32.6% (60 months). Decrements in physical QoL were found at 2, 6, 12, 24, 36, and 48 months compared with baseline. Life satisfaction ratings were lower at 6 months compared with baseline. Sexual concerns were consistently high across the 5 years (Expanded Prostate Cancer Index Composite <30).

In the context of advanced disease, results indicate that health-related QoL fluctuates from diagnosis to 5 years later. A substantial proportion remained distressed at 5-year follow-up.

Care frameworks supporting ongoing assessment of health-related QoL concerns of men with advanced prostate cancer are needed with a particular focus on sexual adjustment.

Cancer nursing. 2017 Mar 10 [Epub ahead of print]

Leah Zajdlewicz, Melissa K Hyde, Stephen J Lepore, Robert A Gardiner, Suzanne K Chambers

Author Affiliations: Cancer Council Queensland, Brisbane, and Menzies Health Institute Queensland, Griffith University, Gold Coast, Australia (Ms Zajdlewicz and Dr Hyde and Prof Chambers); Department of Social and Behavioral Sciences, Temple University, Philadelphia, Pennsylvania (Prof Lepore); University of Queensland Centre for Clinical Research, The University of Queensland, Brisbane (Prof Gardiner); and Prostate Cancer Foundation of Australia, Sydney, and Exercise Medicine Research Institute, Edith Cowan University, Perth (Prof Chambers), Australia.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.